New dye technique may help surgeons spot hidden cancer spread
NCT ID NCT05191212
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a modified method for injecting a green dye (indocyanine green) to help surgeons see lymph nodes during robotic surgery for early-stage endometrial cancer. The new approach injects the dye until the lymphatic channels are visible in real time, aiming to improve detection of sentinel lymph nodes on both sides of the pelvis. The trial enrolled 80 patients and compared this technique with the standard injection method.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- indocyanine green (ICG)
- What this could lead to
- If the modified technique proves better, it could improve the accuracy of sentinel lymph node detection during surgery for early-stage endometrial cancer.
- What could go wrong
- This is a small, single-center study with 80 participants, so results may not apply broadly. The intervention is a procedural variation, not a new drug or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Sep 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients with clinical stage 1-2 endometrial cancer ASA 1-3 patients. Ability to provide written informed consent Exclusion Criteria: Patients with clinical stage 3-4 endometrial cancer Patients who are not suitable for robotic surgery due to their comorbidities (such as glaucoma, COPD, asthma) ASA 4-5 patients. Patients unable or unwilling to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gökhan Demirayak
Istanbul, 34147, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
- Your gut bacteria may hold the key to whether immunotherapy works
- AI reads tumor slides to match cancer patients with trials
- Hormone blockers and letrozole tested to spare uterus in early endometrial cancer